01—Abstract
Summary
Summary of the 10-K filed February 13, 2026. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2025 10-K shows a company at an inflection point: total revenues rose 9% to $12.0 billion, operating income swung to $4.2 billiona from a $232.9 million loss in 2024 (which had been depressed by a $4.4 billion non-deductible Alpine acquisition charge), and net income reached $3.95 billion, or $15.32 diluted EPS.
The core CF franchise remains the economic engine, with TRIKAFTA/KAFTRIO generating $10.3 billionb, roughly 86% of product revenue, while newer launches are gaining traction: ALYFTREK contributed $837.8 million, CASGEVY $115.8 million and JOURNAVX $59.6 million. Operating cash flow recovered to $3.6 billion, and cash plus marketable securities grew to $12.3 billion, supporting a $4.0 billion buyback authorization with $3.4 billion still available. The investment case increasingly depends on the pipeline rather than CF.
Management expects to complete the povetacicept BLA for IgA nephropathy in the first half of 2026 using a priority review voucher, with interim data pending, and plans to report AMKD interim data in late 2026 or early 2027. Management also expects SG&A and cost of sales to rise in 2026 as JOURNAVX, povetacicept and CASGEVY scale. Key risks include ongoing pricing pressure (the IRA, state PDABs and the proposed GUARD model), the Royalty Pharma arbitration over the ALYFTREK royalty rate (Vertex accounts for 4%, RP asserts roughly 8%), the $379 millionc impairment of the VX-264 T1D asset, the temporary pause in zimislecel dosing pending a manufacturing analysis, and the August 2025 setback for suzetrigine in broad peripheral neuropathic pain.
At the balance-sheet level the company is conservative: it has no drawn debt on its $500 milliond revolver, an effective tax rate of 14.9%, and a clean audit opinion from Ernst & Young with an unqualified internal-control opinion. Concentration remains high, since substantially all product revenue comes from CF medicines and McKesson accounts for 22% of gross product revenue.
02—Key points
Key Highlights
- Revenue growth: Total revenues rose 9% to $12.0 billion (2024: $11.0 billion), led by TRIKAFTA/KAFTRIO ($10.3 billion, +1%) and new launches ALYFTREK ($837.8 million), CASGEVY ($115.8 million) and JOURNAVX ($59.6 million).
- Profitability rebound: Income from operations was $4.2 billion versus a $232.9 million loss in 2024, which included a $4.4 billion non-deductible AIPR&D charge for the Alpine acquisition. Net income was $3.95 billion, or $15.32 per diluted share, against a $535.6 million loss in 2024.
- Operating cost pressure: R&D rose 8% to $3.9 billion and SG&A rose 20% to $1.75 billion, driven by JOURNAVX commercialization and pipeline spending. A $379.0 million intangible impairment was recorded on the VX-264 T1D program, which was discontinued.
- Cash generation and balance sheet: Operating cash flow was $3.6 billion (2024: negative $492.6 million). Cash, equivalents and marketable securities reached $12.3 billion, and the $500 million credit facility remains undrawn.
- Capital return: Vertex repurchased $2.0 billion of stock in 2025 under its programs, and $3.4 billion of the $4.0 billion 2025 authorization remains available. The company has never paid a cash dividend.
- Pipeline catalysts for 2026: Povetacicept BLA completion for IgAN (first half of 2026, using a priority review voucher), IgAN interim data, pMN Phase 3 start (mid-2026), CASGEVY pediatric submissions (first half of 2026), and AMKD interim data (late 2026 or early 2027).
- Key risks: The ALYFTREK royalty arbitration brought by Royalty Pharma (asserted rate ~8% versus Vertex's 4%), U.S. and ex-U.S. pricing pressure including the IRA and proposed GUARD model, CF revenue concentration, and China-based supply dependencies.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Vertex Pharmaceuticals Inc kept $0.33.
- Revenue$12.00B100.0%
- Cost of revenue−$1.65B13.8%
- Gross profit$10.35B86.2%
- Operating costs−$6.18B51.5%
- Operating income$4.17B34.8%
- Interest, other & tax−$220.1M1.8%
- Net income$3.95B32.9%
Where FY2025 revenue went
$12.00B- Other operating costs: $4.42B, 37% of revenue
- Net income: $3.95B, 33% of revenue
- SG&A: $1.75B, 15% of revenue
- Cost of revenue: $1.65B, 14% of revenue
- Interest, other & tax: $220.1M, 1.8% of revenue
Kept 33% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 13, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $12.00B$11.02B | +8.9% |
| Cost of Revenue | $1.65B$1.53B | +7.9% |
| Gross Profit | $10.35B$9.49B | +9.1% |
| SG&A Expenses | $1.75B$1.46B | +19.7% |
| Operating Expenses | $7.83B$11.25B | −30.4% |
| Operating Income | $4.17B-$232.90M | +1891.9% |
| Net Income | $3.95B-$535.60M | +838.1% |
| EPS (Basic) | $15.46$-2.08 | +843.3% |
| EPS (Diluted) | $15.32$-2.08 | +836.5% |
| Shares Outstanding (Basic) | 255.70M257.90M | −0.9% |
| Shares Outstanding (Diluted) | 258.00M257.90M | 0.0% |
05—Questions
Frequently Asked Questions
How dependent is Vertex on its cystic fibrosis franchise?
Very dependent. Substantially all net product revenue comes from CF medicines, and TRIKAFTA/KAFTRIO alone produced $10.3 billion of the $12.0 billion total in 2025, about 86% of product revenue. Management is building diversification through ALYFTREK, CASGEVY, JOURNAVX and the pipeline, but these contributed only about $1.0 billion combined in 2025. Investors should watch whether next-generation CF products and the transition to ALYFTREK sustain CF growth.
What is the Royalty Pharma arbitration about, and how material could it be?
Royalty Pharma, which holds the CFF's royalty rights, started a confidential arbitration in October 2025 asserting that the royalty burden on ALYFTREK is about 8%. Vertex maintains it is 4% under the CFF Agreement and intends to defend that position vigorously. The 10-K says that if the arbitration goes against Vertex, future cost of goods could rise. No loss contingency is accrued, and the filing does not quantify a potential exposure.
What is the outlook for 2026 operating expenses and margins?
Management expects total revenues to grow in 2026, driven by CF growth, ALYFTREK expansion, and higher CASGEVY and JOURNAVX contributions. Cost of sales as a percentage of net product revenue is expected to increase because a larger share of revenue will come from non-CF products, which have higher manufacturing costs relative to revenue. R&D expenses are expected to keep rising, particularly T1D, and SG&A is expected to grow with the JOURNAVX expansion and the anticipated povetacicept IgAN launch.
What are the main near-term pipeline risks and catalysts?
Near-term catalysts include the povetacicept IgAN interim analysis and BLA completion in the first half of 2026, AMKD interim data in late 2026 or early 2027, and the pMN Phase 3 start in mid-2026. Risks include zimislecel dosing being temporarily postponed pending an internal manufacturing analysis, the earlier VX-264 failure, and FDA indicating in 2025 that it did not see a path to a broad neuropathic pain label for suzetrigine at that time. Clinical and regulatory timing is inherently uncertain, and interim data may not predict final results.
How strong is Vertex's liquidity and capital allocation position?
Liquidity is strong. Cash, cash equivalents and marketable securities total $12.3 billion, and working capital is $7.3 billion. Operating cash flow was $3.6 billion in 2025, and management expects existing cash plus product cash flows to fund operations for at least the next twelve months. The $500 million revolver is undrawn and matures in July 2027. Vertex has no funded debt and has been returning capital through buybacks ($2.0 billion in 2025), with $3.4 billion of authorization remaining.
06—Continue